Name | 4-(4-fluorophenyl)-2,4-dihydroxy-N,5-diphenyl-2-propan-2-yl-3,6-dioxabicyclo[3.1.0]hexane-1-carboxamide |
---|---|
Synonyms |
atorvastatin calcium epoxide dihydroxy
Atorvastatin Epoxy Tetrahydrofuran Impurity ATV-epoxy furan Atorvastatin Impurity 5 |
Description | Atorvastatin Epoxy Tetrahydrofuran Impurity is an impurity isolated oxidative degradation products of Atorvastatin (HY-B0589)[1]. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. |
---|---|
Related Catalog | |
In Vitro | Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation. |
References |
Molecular Formula | C26H24FNO5 |
---|---|
Molecular Weight | 449.47100 |
Exact Mass | 449.16400 |
PSA | 94.81000 |
LogP | 4.29830 |
Hazard Codes | Xi |
---|
~% 873950-19-7 |
Literature: TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC. Patent: WO2006/37125 A1, 2006 ; Location in patent: Page/Page column 17 ; |